Innovative treatment for late stage Parkinson’s disease could be launched in Europe


Author: Saskia MairPublished: 8 October 2020

Parkinson's LifePrep: Parkinson's LifeCook: Parkinson's LifeServes:

A wearable pump that delivers an infusion of medications to tackle motor symptoms in people living with late stage Parkinson’s disease has just been acquired by European pharmaceutical company STADA

An innovative therapy using an infusion pump, created to treat late stage Parkinson’s disease, could be launched to European markets.

Designed to treat motor symptoms that cannot be treated by oral medication, the gel formula contains an infusion of Parkinson’s medications, and is delivered to the patient’s small intestine through a lightweight, wearable pump.

The therapy, which has been approved in Sweden, Denmark, Norway and Finland, was recently acquired by German pharmaceutical company STADA. The company already has a range of treatments for late stage Parkinson’s disease through its subsidiary Britannia Pharmaceuticals – but the team there hopes that it will be able to extend patient access to the device, and improve patient quality of life.

Dominic Graham, operations director at the European Parkinson’s Disease Association, explained how the treatment could improve the lives of people living with the condition: “Very often people with Parkinson’s experience significant uncertainty because their condition can rapidly switch between being able to move and being immobile. Infusion pump treatments provide invaluable security, as well as an opportunity to plan and have control over daily life.”

Dag Nyholm, associate professor of neurology at Uppsala University, Sweden, added that these treatment innovations were crucial to helping patients manage symptoms.

“Parkinson’s disease patients and their clinical teams have an urgent need for next-generation therapies that can improve lives, such as by increasing therapy adherence or reducing side effects. Continuous improvement of the management of Parkinson’s disease, such as infusion pump therapies and deep brain stimulation, is important,” he said.

“The field is moving forwards in several areas; for example, exciting new approaches to try to modify the course of the disease. However, we have to keep improving the symptomatic treatments to give our patients the best possible quality of life, in spite of the degenerative nature of the disease.”

Find out more about the innovative Parkinson’s disease therapy here.

Read more:

Cutting-edge technologies that could treat Parkinson’s

The women blazing the trail in Parkinson’s tech and innovation

Go Back

Share this story


Related articles

Global Kinetic PKG Lead

sponsored article

Resources & Tools

How Parkinson’s wearables can deliver accurate data from patient to neurologist

VIDEO: Discover the powerful possibilities of wearable tech

Portland Sleep and PD

Resources & Tools

Trouble sleeping? Listen to a free podcast about sleep and Parkinson’s

Discussing a common nocturnal nemesis for people with Parkinson's

Glen Tiptonn returns to stage

Global update

Watch: Judas Priest guitarist Glenn Tipton returns to stage after Parkinson’s diagnosis

The guitarist was back in action at a rock festival in Sweden